BIOGEN INC (1BIIB.MI) Fundamental Analysis & Valuation

BIT:1BIIB • US09062X1037

Current stock price

151.34 EUR
+6.89 (+4.77%)
Last:

This 1BIIB.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. 1BIIB.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1BIIB was profitable.
  • In the past year 1BIIB had a positive cash flow from operations.
  • Each year in the past 5 years 1BIIB has been profitable.
  • 1BIIB had a positive operating cash flow in each of the past 5 years.
1BIIB.MI Yearly Net Income VS EBIT VS OCF VS FCF1BIIB.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 4.39%, 1BIIB is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
  • The Return On Equity of 1BIIB (7.08%) is better than 79.01% of its industry peers.
  • The Return On Invested Capital of 1BIIB (8.93%) is better than 81.48% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1BIIB is below the industry average of 11.35%.
  • The 3 year average ROIC (8.93%) for 1BIIB is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
1BIIB.MI Yearly ROA, ROE, ROIC1BIIB.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • 1BIIB's Profit Margin of 13.07% is fine compared to the rest of the industry. 1BIIB outperforms 79.01% of its industry peers.
  • In the last couple of years the Profit Margin of 1BIIB has declined.
  • Looking at the Operating Margin, with a value of 27.94%, 1BIIB belongs to the top of the industry, outperforming 85.19% of the companies in the same industry.
  • In the last couple of years the Operating Margin of 1BIIB has declined.
  • Looking at the Gross Margin, with a value of 75.69%, 1BIIB is in the better half of the industry, outperforming 64.20% of the companies in the same industry.
  • 1BIIB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
1BIIB.MI Yearly Profit, Operating, Gross Margins1BIIB.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. 1BIIB.MI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 1BIIB is still creating some value.
  • Compared to 1 year ago, 1BIIB has more shares outstanding
  • Compared to 5 years ago, 1BIIB has less shares outstanding
  • The debt/assets ratio for 1BIIB has been reduced compared to a year ago.
1BIIB.MI Yearly Shares Outstanding1BIIB.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
1BIIB.MI Yearly Total Debt VS Total Assets1BIIB.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • 1BIIB has an Altman-Z score of 3.31. This indicates that 1BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.31, 1BIIB is doing good in the industry, outperforming 65.43% of the companies in the same industry.
  • 1BIIB has a debt to FCF ratio of 3.11. This is a good value and a sign of high solvency as 1BIIB would need 3.11 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.11, 1BIIB belongs to the top of the industry, outperforming 83.95% of the companies in the same industry.
  • A Debt/Equity ratio of 0.34 indicates that 1BIIB is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.34, 1BIIB perfoms like the industry average, outperforming 59.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.31
ROIC/WACC1.08
WACC8.25%
1BIIB.MI Yearly LT Debt VS Equity VS FCF1BIIB.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that 1BIIB has no problem at all paying its short term obligations.
  • The Current ratio of 1BIIB (2.68) is comparable to the rest of the industry.
  • A Quick Ratio of 2.03 indicates that 1BIIB has no problem at all paying its short term obligations.
  • 1BIIB has a Quick ratio of 2.03. This is comparable to the rest of the industry: 1BIIB outperforms 48.15% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
1BIIB.MI Yearly Current Assets VS Current Liabilites1BIIB.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. 1BIIB.MI Growth Analysis

3.1 Past

  • The earnings per share for 1BIIB have decreased by -7.16% in the last year.
  • Measured over the past years, 1BIIB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.17% on average per year.
  • The Revenue has been growing slightly by 2.22% in the past year.
  • The Revenue has been decreasing by -5.96% on average over the past years.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.53% on average over the next years.
  • 1BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.48% yearly.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.94%
Revenue Next 2Y-2.41%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1BIIB.MI Yearly Revenue VS Estimates1BIIB.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
1BIIB.MI Yearly EPS VS Estimates1BIIB.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. 1BIIB.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.44, the valuation of 1BIIB can be described as very reasonable.
  • 1BIIB's Price/Earnings ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 92.59% of the companies in the same industry.
  • 1BIIB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.78.
  • Based on the Price/Forward Earnings ratio of 10.88, the valuation of 1BIIB can be described as reasonable.
  • 1BIIB's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 92.59% of the companies in the same industry.
  • 1BIIB's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.54.
Industry RankSector Rank
PE 11.44
Fwd PE 10.88
1BIIB.MI Price Earnings VS Forward Price Earnings1BIIB.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1BIIB indicates a rather cheap valuation: 1BIIB is cheaper than 90.12% of the companies listed in the same industry.
  • 1BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1BIIB is cheaper than 93.83% of the companies in the same industry.
Industry RankSector Rank
P/FCF 12.71
EV/EBITDA 8.12
1BIIB.MI Per share data1BIIB.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • 1BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.22
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1BIIB.MI Dividend Analysis

5.1 Amount

  • No dividends for 1BIIB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

1BIIB.MI Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

BIT:1BIIB (4/9/2026, 7:00:00 PM)

151.34

+6.89 (+4.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap22.21B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target176.97 (16.94%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)8.35%
PT rev (3m)14.86%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-12.62%
EPS NY rev (1m)4.09%
EPS NY rev (3m)2.98%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.82%
Revenue NY rev (1m)1.18%
Revenue NY rev (3m)1.73%
Valuation
Industry RankSector Rank
PE 11.44
Fwd PE 10.88
P/S 2.59
P/FCF 12.71
P/OCF 11.64
P/B 1.41
P/tB 9.92
EV/EBITDA 8.12
EPS(TTM)13.23
EY8.74%
EPS(NY)13.91
Fwd EY9.19%
FCF(TTM)11.91
FCFY7.87%
OCF(TTM)13
OCFY8.59%
SpS58.32
BVpS107.66
TBVpS15.26
PEG (NY)2.22
PEG (5Y)N/A
Graham Number179.02
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.31
F-Score4
WACC8.25%
ROIC/WACC1.08
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.94%
Revenue Next 2Y-2.41%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / 1BIIB.MI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOGEN INC (1BIIB.MI) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1BIIB.MI.


What is the valuation status of BIOGEN INC (1BIIB.MI) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (1BIIB.MI). This can be considered as Undervalued.


What is the profitability of 1BIIB stock?

BIOGEN INC (1BIIB.MI) has a profitability rating of 6 / 10.


What is the valuation of BIOGEN INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIOGEN INC (1BIIB.MI) is 11.44 and the Price/Book (PB) ratio is 1.41.